Table 2.
Independent clinical parameters significantly associated with a pCR.
| Parameter | OR | 95% CI | P value∗ |
|---|---|---|---|
| Chemotherapy (FOLFOX vs. non-FOLFOX) | 5.385 | 1.699–17.688 | 0.0044 |
| Clinical N stage (N0 vs. N1/2) | 3.200 | 1.279–8.410 | 0.0135 |
| Anemia during CRT (Hb > 10 vs. Hb≤ 10) | 3.067 | 1.251–8.187 | 0.0125 |
| Post-CRT CEA (≤2 vs. > 2) | 2.891 | 1.156–7.369 | 0.0233 |
| RT to surgery interval (>8 weeks vs. ≤8 weeks) | 1.135 | 1.021–5.712 | 0.0469 |
| Gender (male vs. female) | 0.607 | 0.291–1.265 | 0.1823 |
| Age (≤60 vs. > 60) | 0.680 | 0.329–1.265 | 0.2850 |
| Location of tumor (middle/low vs. upper) | 1.895 | 0.911–4.068 | 0.0877 |
| Grade (WD/MD vs. PD) | 0.349 | 0.064–2.113 | 0.2373 |
| Clinical T stage (T2/3 vs. T4) | 1.810 | 0.615–6.186 | 0.2907 |
| Radiation dose (<5000 vs. ≥ 5000) | 0.626 | 0.186–1.799 | 0.3972 |
| Pre-CRT CEA (≤5 vs. > 5) | 1.761 | 0.861–3.727 | 0.1221 |
| Leukopenia during CRT(WBC>3000 vs. WBC≤3000) | 0.833 | 0.378–1.826 | 0.6479 |
| Cycles of pre-OP chemotherapy(≥7 vs. < 7) | 1.037 | 0.656–1.625 | 0.8732 |
| ycT stage (T0-2 vs. T3-4) | 1.872 | 0.886–4.110 | 0.1008 |
| ycN stage (N0 vs. N1/2) | 1.624 | 0.799–3.311 | 0.1788 |
CEA, carcinoembryonic antigen; CRT, chemoradiation therapy; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; Hb, hemoglobin; OP, operative; pCR, pathological complete response; RT, radiation therapy; WBC, white blood cell; ycT stage: clinical tumor stage after chemoradiotherapy; ycN stage: clinical nodal stage after chemoradiotherapy. ∗Logistic regression.